A. Paltiel, A. Zheng, J. L. Schwartz
Annals of Internal Medicine, 2021
The global effort to develop a vaccine for coronavirus disease 2019 (COVID-19) has already produced 2 candidates, each requiring 2 doses, with reported efficacies exceeding 90% The US Food and Drug Administration (FDA) has granted Emergency Use Authorization for both vaccines (Pfizer-BioNTech and Moderna) Their reported efficacies greatly exceed the 50% threshold the FDA cited in a June 2020 guidance document Additional vaccine candidates at earlier stages of development hold the promise of single dosing, simpler storage requirements, and more rapid immunity after vaccination Here, a study that aims to quantify the speed-versus-efficacy tradeoff using a previously published model of a COVID-19 vaccination program is offered
Cited by 22 publications.
Field of study: Medicine